AU2021337798A1 - Mesenchymal stem cells co-expressing cxcr4 and il-10 and uses thereof - Google Patents

Mesenchymal stem cells co-expressing cxcr4 and il-10 and uses thereof Download PDF

Info

Publication number
AU2021337798A1
AU2021337798A1 AU2021337798A AU2021337798A AU2021337798A1 AU 2021337798 A1 AU2021337798 A1 AU 2021337798A1 AU 2021337798 A AU2021337798 A AU 2021337798A AU 2021337798 A AU2021337798 A AU 2021337798A AU 2021337798 A1 AU2021337798 A1 AU 2021337798A1
Authority
AU
Australia
Prior art keywords
mscs
cxcr4
cells
expression cassette
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021337798A
Other languages
English (en)
Inventor
Juan Antonio Bueren Roncero
María FERNÁNDEZ GARCÍA
Mariano GARCÍA-ARRANZ
Damián GARCÍA-OLMO
Marina Inmaculada GARIN FERREIRA
Miriam HERNANDO RODRÍGUEZ
Rosario HERVÁS-SALCEDO
Mercedes LÓPEZ SANTALLA
Rosa María Yáñez González
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas
Centro de Investigación Biomédica en Red
Hospital Universitario Fundación Jiménez Díaz
Original Assignee
Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas
Centro de Investigación Biomédica en Red
Hospital Universitario Fundación Jiménez Díaz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigación Biomédica en Red, Hospital Universitario Fundación Jiménez Díaz filed Critical Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas
Publication of AU2021337798A1 publication Critical patent/AU2021337798A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2021337798A 2020-09-07 2021-09-07 Mesenchymal stem cells co-expressing cxcr4 and il-10 and uses thereof Pending AU2021337798A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382792.8 2020-09-07
EP20382792.8A EP3964265A1 (en) 2020-09-07 2020-09-07 Mesenchymal stem cells co-expressing cxcr4 and il-10 and uses thereof
PCT/EP2021/074612 WO2022049306A1 (en) 2020-09-07 2021-09-07 Mesenchymal stem cells co-expressing cxcr4 and il-10 and uses thereof

Publications (1)

Publication Number Publication Date
AU2021337798A1 true AU2021337798A1 (en) 2023-05-18

Family

ID=72473480

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021337798A Pending AU2021337798A1 (en) 2020-09-07 2021-09-07 Mesenchymal stem cells co-expressing cxcr4 and il-10 and uses thereof

Country Status (11)

Country Link
US (1) US20230398152A1 (enExample)
EP (2) EP3964265A1 (enExample)
JP (2) JP2023540599A (enExample)
KR (1) KR20230082622A (enExample)
CN (1) CN116507733A (enExample)
AU (1) AU2021337798A1 (enExample)
BR (1) BR112023004167A2 (enExample)
CA (1) CA3194344A1 (enExample)
MX (1) MX2023002741A (enExample)
SA (1) SA523442866B1 (enExample)
WO (1) WO2022049306A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12624086B2 (en) 2018-10-31 2026-05-12 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer
US12264189B2 (en) 2018-10-31 2025-04-01 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US12257286B2 (en) 2018-10-31 2025-03-25 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN115927178A (zh) * 2022-11-17 2023-04-07 华夏源(上海)生物科技有限公司 一种检测间充质干细胞抑制b细胞分化为浆细胞的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69637856D1 (en) * 1996-08-30 2009-04-16 Human Genome Sciences Inc Interleukin-19.
CA2566267A1 (en) * 2005-12-09 2007-06-09 University Health Network Thymidylate kinase mutants and uses thereof
CA2784861A1 (en) * 2009-12-21 2011-07-14 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof
PL3242933T3 (pl) * 2015-01-08 2019-08-30 Apceth Gmbh & Co. Kg Zmodyfikowane genetycznie mezenchymalne komórki macierzyste wykazujące ekspresję alfa-1 antytrypsyny (aat)
EP3487991B1 (en) * 2016-07-25 2022-09-07 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of producing modified natural killer cells and methods of use
JP7493497B2 (ja) * 2018-06-19 2024-05-31 フォンダッツィオーネ・テレソン・エティエッセ 操作された樹状細胞の生産及びその使用

Also Published As

Publication number Publication date
CA3194344A1 (en) 2022-03-10
SA523442866B1 (ar) 2024-05-05
US20230398152A1 (en) 2023-12-14
MX2023002741A (es) 2023-05-26
JP2026082892A (ja) 2026-05-19
WO2022049306A1 (en) 2022-03-10
JP2023540599A (ja) 2023-09-25
KR20230082622A (ko) 2023-06-08
EP3964265A1 (en) 2022-03-09
EP4210834A1 (en) 2023-07-19
CN116507733A (zh) 2023-07-28
BR112023004167A2 (pt) 2023-05-09

Similar Documents

Publication Publication Date Title
Huang et al. Targeted homing of CCR2-overexpressing mesenchymal stromal cells to ischemic brain enhances post-stroke recovery partially through PRDX4-mediated blood-brain barrier preservation
US20230398152A1 (en) Mesenchymal stem cells co-expressing cxcr4 and il-10 and uses thereof
JP6920644B2 (ja) 幹細胞の免疫制御作用を調節する方法
US11464806B2 (en) Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
JP5095403B2 (ja) 治療的応用法のための遺伝的に改変された細胞
KR101764643B1 (ko) 중간엽 줄기 세포의 용도
Hervás-Salcedo et al. Enhanced anti-inflammatory effects of mesenchymal stromal cells mediated by the transient ectopic expression of CXCR4 and IL10
US20110150845A1 (en) Methods and compositions for modulating immunological tolerance
EP1542701A1 (en) Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
CN104822384A (zh) 用于间充质干细胞诱导的免疫调节的组合物和治疗方法
IL280465B1 (en) Methods for gene modification of hematopoietic cells
Liu et al. Over-expression of CXCR4 on mesenchymal stem cells protect against experimental colitis via immunomodulatory functions in impaired tissue
WO2022117049A1 (zh) Nkg2d car-免疫细胞在抗衰老及老年相关疾病治疗中的应用
EP1771196B1 (en) Ccr ligands for stem cell homing
US9315558B2 (en) Use of interleukin 10 mRNA transfected macrophages in anti-inflammatory therapies
EP4289859A1 (en) Fusion protein for maintenance of regulatory t-cells
US20250353889A1 (en) Fusion protein for maintenance of regulatory t-cells
Gkountidi et al. MHC class II antigen presentation by tumoral lymphatics is required for tumor specific signature and suppressive functions of Tregs
WO2023122099A2 (en) Crispr-based gene editing to preserve splicing and expression of foxp3 isoforms 1 and 2
Gabay et al. Interleukin-18 and interleukin-18 binding protein balance: focus on IL-18BP production and IL-18 maturation in macrophage activation syndrome
HK40008045A (en) Methods modulating immunoregulatory effect of stem cells